| Document |
Document Title |
|
WO/2021/123360A1 |
The present invention relates to the field of affinity purification and provides for means and methods applying protein binding agents competing for a target protein for use as capture and elution tool, wherein the elution agent comprise...
|
|
WO/2021/122943A1 |
The present invention relates to the field of protein purification and relates in particular to novel proteins that bind specifically to acid alpha glucosidase (GAA). The invention further relates to fusion proteins comprising novel prot...
|
|
WO/2021/124627A1 |
The present invention relates to a synthesis device for chemically synthesizing a protein, a peptide, a nucleic acid or the like in a reaction vessel having a support arranged thereon, and addresses the problem of reducing the support th...
|
|
WO/2021/114788A1 |
The present invention relates to the technical field of impurity synthesis, and particularly to a teriparatide impurity F. It is discovered that aspartimide impurities will be produced during the production and storage process of teripar...
|
|
WO/2021/119404A1 |
Method and system for purifying a sample comprising a biomolecule of interest and impurities, comprising expressing said biomolecule of interest in a bioreactor to form a product sample comprising said biomolecule of interest and impurit...
|
|
WO/2021/114787A1 |
Disclosed is a teriparatide-aspartimide impurity, named impurity F. In addition, provided is a solid-phase method of synthesizing impurity F.
|
|
WO/2021/115258A1 |
Disclosed in the present invention is an FGFR antagonistic short peptide, i.e. a short peptide compound P48, the amino acid sequence thereof is Ser-Pro-Pro-Arg-Tyr-Pro-Gly-Gly-Gly-Ser-NH2. The short peptide compound P48 inhibits cell pro...
|
|
WO/2021/115237A1 |
The present application belongs to the technical field of medical biomaterials, and specifically relates to a green and broad-spectrum protein cross-linking method. The method uses a visible light source having composite wavelengths to i...
|
|
WO/2021/116273A2 |
The present invention relates to a method for continuous recovering of a protein from a fluid, comprising precipitating the protein in the fluid and separating the precipitated protein from the fluid. The invention also provides an incli...
|
|
WO/2021/116110A1 |
The invention is concerned with manufacturing a fibrinogen preparation from a fibrinogen containing source derived from blood plasma. The method comprising the steps, providing a liquid phase containing plasmatic fibrinogen; contacting t...
|
|
WO/2021/118963A1 |
This disclosure relates to a method which involves the steps of: (a) providing an aqueous solution comprising a protein and a polyalkoxy fatty acyl surfactant of general formula (I), wherein R1-C(=0) is a fatty acyl group, R2 is H or a s...
|
|
WO/2021/118900A1 |
The invention provides methods of using environmentally compatible detergents in the field of recombinant protein manufacturing for inactivating viruses in a product feedstream in the manufacturing process of proteins intended for admini...
|
|
WO/2021/119639A1 |
Compositions, systems and methods for measuring secretion of a protein-of- interest that include trap proteins and reporter proteins for secretion by a cell. Each trap protein comprises a binding partner, a first fluorescent label, and a...
|
|
WO/2021/114713A1 |
A cell lysis solution, a kit, and an application, comprising a cell lysis method, a library construction method, and an application thereof. The cell lysis solution is composed of proteinase K and NP-40, has a simple composition, and can...
|
|
WO/2021/109297A1 |
Disclosed are an etelcalcetide intermediate and a method for synthesizing etelcalcetide. The etelcalcetide intermediate is Fmoc-D-Cys(S-S-(N-Boc)-L-Cys(OtBu))-OH. The method for synthesizing etelcalcetide comprises the following steps: u...
|
|
WO/2021/112925A1 |
The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.
|
|
WO/2021/110468A1 |
A porous membrane obtainable by a process comprising curing a composition comprising: (i) cross-linking agent(s); (ii) monomer(s) comprising one polymerisable group and at least one ligand group; (iii) inert solvent(s); and (iv) polymeri...
|
|
WO/2021/112927A1 |
The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.
|
|
WO/2021/109177A1 |
Provided is an immunoglobulin binding protein, including variants of the B domain of protein A, the C2 domain of protein G, and the B3 domain of protein L, or a combination of any 1-3 variants. Provided are also a method for purifying th...
|
|
WO/2021/112923A1 |
The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.
|
|
WO/2021/103458A1 |
Provided is a solid-phase synthesis method for degarelix. The solid-phase synthesis method comprises: 1) coupling of a peptide resin: according to an Fmoc solid phase synthesis method, coupling amino acids Fmoc-D-Ala-OH, Fmoc-Pro-OH, Fmo...
|
|
WO/2021/103454A1 |
Provided is a desalination method using the lyophilization principle, comprising: eluting volatile salt; and performing vacuum freeze drying to remove related salts, to control acid radical content.
|
|
WO/2021/104435A1 |
Provided is a biological magnetic microsphere, comprising a magnetic microsphere body. The magnetic microsphere body comprises, on an outer surface thereof, at least one polymer having a linear main chain and a side chain. An end of the ...
|
|
WO/2021/108237A1 |
The present invention relates to a method of measuring at least one product quality attributes, including critical quality attributes (e.g., oxidation, C-terminal lysine, aggregation, N-terminal glutamine cyclization.) by an online liqui...
|
|
WO/2021/104509A1 |
Disclosed are a method for treating a silk fibroin with an aromatic alcohol and the use thereof in the preparation of a silk-fibroin-containing material. The method for treating a silk fibroin comprises the following steps: bringing a si...
|
|
WO/2021/107660A1 |
The present invention provides a multifunctional multispecific multimeric biomolecule polymer which is formed by obtaining a biomolecule, to which a ubiquitin C-terminal tag is bound, by recombinant-expressing the biomolecule from a host...
|
|
WO/2021/105864A1 |
Described herein is a method of purifying a target molecule from an aqueous biological composition, the method comprising: (a) contacting a cationic polymer and the aqueous biological composition to form a mixture comprising a bio-polyme...
|
|
WO/2021/103059A1 |
Disclosed is the use of an aromatic alcohol as a silk fibroin inducer. Also disclosed a method for treating silk fibroin, the method comprising the following steps: bringing the silk fibroin into contact with steam or liquid containing t...
|
|
WO/2021/102624A1 |
Provided a proximity-enabled reactive therapeutics (PERx) approach to generate covalent protein drugs. A latent bioreactive amino acid FSY was incorporated into human programmed cell death protein 1 (PD-1), which selectively reacted with...
|
|
WO/2021/106000A1 |
The invention provides a method of preparing a biaryl-bridged cyclic peptide compound of Formula (I), where R1, R2, R3, R4, R5, R8, R7, R8, R9, R10, R11, R12, n and m are as defined in the specification. The biaryl-bridged cyclic peptide...
|
|
WO/2021/099529A1 |
The present invention relates to a method and system for extracting proteins from precipitates, particularly recombinant and/or plasma derived proteins including immunoglobulins (Ig) such as immunoglobulin G (IgG).
|
|
WO/2021/102322A1 |
Cyclic peptides that inhibit MDM2 or MDM2 and MDM4, pharmaceutical compositions containing these cyclic peptides, and methods of using these cyclic peptides for inhibiting MDM2 or MDM2 and MDM4 are described herein.
|
|
WO/2021/100833A1 |
The present invention addresses the problem of developing a method for synthesizing a novel peptide which can co-incorporate a plurality of different N-methyl amino acids and discover a highly N-methylated peptide having improved membran...
|
|
WO/2021/099528A1 |
The present invention relates to an improved method for peak fractionation and eluate collection during chromatography for purification of a human therapeutic antibody.
|
|
WO/2021/099465A1 |
The present invention relates to a method for controlling fraction collection of a target product 27 in a chromatography system 49 configured for cyclic purification performed on a sample comprising the target product 27. The method comp...
|
|
WO/2021/102151A1 |
Disclosed herein is a cyclic peptide polymer. R1, R2, and R3 are organic groups. Each R4 is a covalent bond, methylene, ethylene, n-propylene, or n-butylene. Each X is -NH-, -O-, or -O-CO-. The values m and n are nonnegative integers hav...
|
|
WO/2021/099842A1 |
Provided herein are pentafluorobenzenesulfonamide compounds of Formula (I), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases. These compounds are covalent small mol...
|
|
WO/2021/100814A1 |
The following compound, and a fluorescently labeled biomaterial having the compound. (1) X represents CR7 or N. R1-R7, Q1, and Q2 represent a hydrogen atom, a halogen atom, a cyano group, or a group represented by formula (A), and adja...
|
|
WO/2021/099536A1 |
The present invention relates to a method for increasing antibody yield during antibody purification from a sample by ion exchange chromatography in flow-through mode by pre-conditioning the sample with Tris without the use of NaCl to ad...
|
|
WO/2021/096759A1 |
The present invention relates to the field of protein engineering, molecular imaging, and molecular diagnostics. More particularly, provided herein are novel synthetic aptamers produced using the GyrI-like family of proteins as a scaffol...
|
|
WO/2021/097349A1 |
The present disclosure provides methods and systems for generating biological molecules. The methods and systems may comprise use of a porous membrane. The present disclosure also provides methods and systems of generating porous membranes.
|
|
WO/2021/093588A1 |
A preparation method for a functional nanomagnetic bead for enriching potato ester acyl hydrolase, comprising the following steps: mixing a carboxylated nanomagnetic bead with ethyl-dimethylamine-propylcarbodiimide; activating the nanoma...
|
|
WO/2021/095398A1 |
The present invention provides: a novel and useful compound for performing various treatments on a hydrogen bond material such as a biological sample; and a hydrogen bond material treating agent. This organic ammonium salt, which is so...
|
|
WO/2021/094518A1 |
The present invention discloses a method and apparatus for fully automated iterative polymer synthesis at a large scale.
|
|
WO/2021/096425A1 |
There is provided a cell culture matrix comprising a fungal derived protein. Also provided is a composition comprising the cell culture matrix, a cell culture system comprising the cell culture matrix as described herein, and a method of...
|
|
WO/2021/090856A1 |
The inventors discovered that, by linking an N-unsubstituted-α,α,-disubstituted amino acid, in which the amino group is protected by an electron-withdrawing protecting group, to a peptide compound comprising an N-terminal N-substituted...
|
|
WO/2021/092382A1 |
A method of treating or preventing a microbial infection in a patient is provided, along with a wound irrigation system and a composition in the form of an irrigation liquid for reducing microbial load or preventing microbial infection i...
|
|
WO/2021/087709A1 |
Disclosed is a (1-5)-Gal-(1-6)-Man glycoprotein, which resists fungal infections, and a preparation method therefor. The glycoprotein is designed on the basis of a fungus surface polysaccharide antigen structure, an oligosaccharide antig...
|
|
WO/2021/089862A1 |
A method of extracting a cytoplasmic or periplasmic protein. The method comprises provision of a first cell suspension comprising cells, the cells containing a cytoplasmic or periplasmic protein of interest to be extracted, the first cel...
|
|
WO/2021/089984A1 |
Aspects of the present invention relate to method and systems which provide extended capability, compared to the existing techniques, for studying the important genome-proteome interactions and chromatin folding and dynamics in higher eu...
|
